Due to practical and ethical concerns associated with human experiments, animal models have been essential in cancer research. Vast resources are expended during the development of new cancer therapeutics, and selection of optimal in vivo models should improve this process. Genetically engineered mouse models (GEMM) of cancer have progressively improved in technical sophistication and, accurately recapitulating the human cognate condition, have provided opportunities to accelerate the development of cancer drugs. In this article we consider the different types of animal models used for predicting the results of clinical trials of cancer drugs, and discuss the strengths and weaknesses of each in this regard. In addition, the methods of predicting in vivo models and clinical translation are discussed.
[1] Frese KK, Tuveson DA. Maximizing mouse cancer models [J]. Nat Rev Cancer, 2007, 7: 645-658.
[2] Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development [J]. Nat Rev Drug Discov. 2006, 5: 741-754.
[3] Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis [J]. Cell, 1994, 79: 185-188.
[4] Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic [J]. Invest New Drugs, 1999, 17: 343-359.
[5] Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges [J]. Cell, 2002, 108: 135-144.
[6] Olive KP, Jacobetz MA, Dacidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer [J]. Science, 2009, 324: 1457-1461.
[7] Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models [J]. Nat Biotechnol, 2010, 28: 585-593.
[8] Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics [J]. Clin Cancer Res, 2006, 12: 5277-5287.
[9] Seaman ME, Contino G, Bardeseey N, et al. Molecular imaging agents: impact on diagnosis and therapeutics in oncology [J]. Expert Rev Mol Med, 2010, 12: E20.
[10] Francia G, Cruz-Munoz W, Man S, et al. Mouse models of advanced spontaneous metastasis for experimental therapeutics [J]. Nat Rev Cancer, 2011, 11: 135-141.
[11] Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148: 349-361.
[12] Matthews RA. Medical progress depends on animal models - doesn't it? [J] J R Soc Med, 2008, 101: 95-98.
[13] Sena ES, van der Worp HB, Bath PM, et al. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy [J]. PLoS Biol., 2010, 8:e1000344.
[14] Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans [J]. JAMA, 2006, 296: 1731-1732.
[15] Fingleton B. Matrix metalloproteinases as valid clinical targets [J]. Curr Pharm Des., 2007, 13:333-346.
[16] Chesler EJ, Wilson SG, Lariviere WR, et al. Identification and ranking of genetic and laboratory environment factors influencing a behavioral trait, thermal nociception, via computational analysis of a large data archive[J]. Neurosci Biobehav Rev, 2002, 26: 907-923.
[17] Schuh JC. Trials, tribulations, and trends in tumor modeling in mice [J]. Toxicol Pathol, 2004, 32 Suppl 1: 53-66.
[18] Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 [J]. N Engl J Med, 2006, 355: 1018-1028.
[19] Vonderheide RH, Nathanson KL. Immunotherapy at large: the road to personalized cancer vaccines [J]. Nat Med, 2013, 19: 1098-1100.
[20] Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future [J]. Oncoimmunology, 2013, 2:e23403.
[21] Ogi C, Aruga A. Immunological monitoring of anticancer vaccines in clinical Trials [J]. Oncoimmunology, 2013, 2: e26012.
[22] Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment [J]. Am J Transl Res, 2014, 6(2): 114-118.
[23] Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials [J]. Br J Cancer 2007; 97: 577-581.
[24] Hay T, Matthews JR, Pietzka L, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin [J]. Cancer Res, 2009, 69: 3850-3855.
[25] Bearss DJ, Subler MA, Hundley JE, et al. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors [J]. Oncogene, 2000, 19:1114-1122.
[26] Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers [J]. Nat Med 2008, 14:1351-1356.
[27] Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition [J]. Proc Natl.Acad Sci U S A., 2009, 106: 19503-19508.
[28] De Raedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors [J]. Cancer Cell, 2011, 20: 400-413.
[29] Hu Y, Swerdlow S, Duffy TM, et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph leukemia in mice [J]. Proc Natl Acad Sci U S A., 2006, 103:16870-16875.
[30] Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia [J]. J Exp Med, 1999, 189:1043-1052.
[31] Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis [J]. Cancer Cell, 2009, 15: 220-231.
[32] Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J]. Cancer Cell, 2005, 8: 299-309.
[33] Chiu CW, Nozawa H, Hanahan D, et al. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis [J]. J Clin Oncol, 2010, 28: 4425-4433.
[34] Schmitt CA, Rosenthal CT, Lowe SW, et al. Genetic analysis of chemoresistance in primary murine lymphomas [J]. Nat. Med., 2000, 6(9): 1029-1035.
[35] Dankort D, Curley DP, Cartlidge RA, et al. Braf (V600E) cooperates with Pten loss to induce metastatic melanoma [J]. Nat Genet, 2009, 41: 544-552.